French
The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar. This will contribute to substantial annual savings that can be reinvested in healthcare and innovative new drugs.
The transition will take place under the supervision of the attending physicians and patients will continue receiving safe and effective treatment. Sandoz Canada has a portfolio of six biosimilars (Omnitrope, Rixymio, Erelzi, Hyrimoz, Ziextenzo and Inclunox).
Sandoz Canada is committed to supporting patients, their healthcare professionals and the Quebec government throughout the transition period with quality biosimilar medicines, medical teams, physician and pharmacist advocacy teams, as well as proven patient support programs.
On May 24, 2021, Zydus Cadila launched the world’s first antibody drug conjugate (ADC) biosimilar. The drug is a trastuzumab emtansine biosimilar - using Genentech’s Kadcyla as the.
Accessa and Québec owner-pharmacists make their debut in the Patient Support Program sector with Sandoz Canada s Hyrimoz® yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
New Brunswick Becomes Third Province in Canada to Implement Biosimilar Switching Policy
News provided by
Share this article
Share this article
TORONTO, April 21, 2021 /CNW/ - Biosimilars Canada, a national association representing Canada s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar switching or transitioning policy to expand the use of biosimilar medicines under the province s public drug plans.
New Brunswick s new biosimilar policy is expected to save the province more than $10 million annually when fully implemented, which will be reinvested to support coverage of new therapies. About 3,000 patients on the province s drug plans who are living with diseases such as arthritis, diabetes, inflammatory bowel disease and psoriasis will have until November 30 to switch from an originator biologic drug to a biosimilar biologic drug.
Article content
New Brunswick joins British Columbia and Alberta in implementing “switch” policy that changes coverage for specific biologic medicines.
Patients switching from reference biologics to biosimilar versions will continue receiving safe, effective treatment while saving millions of dollars every year.
Sandoz Canada is committed to supporting patients, their healthcare professionals, and the New Brunswick Government with high quality biosimilar medicines and experienced, comprehensive patient support programs.
BOUCHERVILLE, Quebec, April 21, 2021 (GLOBE NEWSWIRE) Sandoz Canada, a leader in generic pharmaceuticals and biosimilars, welcomes the New Brunswick Government introduction of a biosimilars switch policy to expand access to high-quality biologic medicines so that patients can benefit from these treatments.